Charles G. Drake

Johnson & Johnson (United States) — United States

Medicine · Health Sciences

133h-index89.9kcitations1.2kworks3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(520), Immunotherapy and Immune Responses(289), Prostate Cancer Treatment and Research(240), Intracranial Aneurysms: Treatment and Complications(113), Immune Cell Function and Interaction(97)

Publications1.2k total

The path forward for T cell engagers in patients with prostate cancer
Journal for ImmunoTherapy of Cancer·2026Open Access
Metabolic Reprogramming of T Cells by Dual UCP2 and IL‐17 Blockade Enhances Immunity Against Pancreatic Cancer
Advanced Science·2026Open Access
Supplementary Figure S6 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Table S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Figure S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Figure S4 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Figure S3 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Figure S7 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Figure S1 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Figure S1 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Figure S5 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Table S1 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Figure S7 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Figure S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Figure S8 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Figure S3 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Table S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Figure S4 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Figure S6 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
2025Open Access
Supplementary Fig. S6 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
2025Open Access
page 1 of 58Next →

Frequent Co-authors

Drew M. Pardoll(16), Suzanne L. Topalian(8), Julie R. Brahmer(6), Janis M. Taube(5), Tomasz M. Beer(5), Lieping Chen(4), Robert A. Anders(4), Alan J. Korman(4), Joseph F. Grosso(4), Monica V. Goldberg(4), Dario A.A. Vignali(4), Karim Fizazi(4), Johann S. de Bono(4), Timothy Harris(4), Sydney J. Peerless(4), F. Stephen Hodi(3), John D. Powderly(3), William H. Sharfman(3), Haiying Xu(3), Ashok Gupta(3)